UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000023963
Receipt No. R000027257
Scientific Title Effects of Single Ingestion of Hydrogen Water (Generated through Hydrogen Water Server) on Blood Flow: A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial
Date of disclosure of the study information 2016/09/10
Last modified on 2017/02/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of Single Ingestion of Hydrogen Water (Generated through Hydrogen Water Server) on Blood Flow: A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial
Acronym Effects of Single Ingestion of Hydrogen Water (Generated through Hydrogen Water Server) on Blood Flow
Scientific Title Effects of Single Ingestion of Hydrogen Water (Generated through Hydrogen Water Server) on Blood Flow: A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial
Scientific Title:Acronym Effects of Single Ingestion of Hydrogen Water (Generated through Hydrogen Water Server) on Blood Flow
Region
Japan

Condition
Condition N/A (healthy adults or adults being sensitive to the cold)
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 This study examines effects of single ingestion of hydrogen water (generated through hydrogen water server) on blood flow.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes [1]Blood flow speed at the end of fingers (Preliminary observation, First observation, Second observation)
[2]Blood flow (First observation, Second observation)
Key secondary outcomes [1]Weight, body fat percentage, BMI (Preliminary observation, First observation, Second observation)
[2]Blood pressure, pulsation (Preliminary observation, First observation, Second observation)
[3]Body temperature (Preliminary observation, First observation, Second observation)
[4]Doctor's questions (Preliminary observation, First observation, Second observation)
[5]Simplified Menopausal Index (Preliminary observation)
[6]Subject's diary (each day during the test period)

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Other
Interventions/Control_1 [1]Oral intake of the test product (hydrogen water, 1 time)
[2]Observation
[3]Washout (1 week)
[4]Oral intake of the placebo product (not hydrogen water, 1 time)
[5]Observation
Interventions/Control_2 [1]Oral intake of the placebo product (not hydrogen water, 1 time)
[2]Observation
[3]Washout (1 week)
[4]Oral intake of the test product (hydrogen water, 1 time)
[5]Observation
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
35 years-old <=
Age-upper limit
60 years-old >
Gender Female
Key inclusion criteria [1]Japanese healthy females aged 35-59 years
[2]Individuals who are sensitive to the cold
[3]Individuals whose written informed consent has been obtained
[4]Individuals who can come to the designated venue for this study and be inspected
[5]Individuals judged appropriate for the study by the principal
Key exclusion criteria [1]Individuals using medical products
[2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia
[3]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis)
[4]Individuals who conducted hormone replacement therapy in the past 3 months or have a history of conducting hormone replacement therapy
[5]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease
[6]Individuals who are a patient or have a history of or endocrine disease
[7]Individuals with serious anemia
[8]Individuals who are sensitive to a test product or other foods, and medical products
[9]Individuals who have a habit to intake hydrogen water
[10]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplyments in the past 3 months or will ingest those foods during the test period
[11]Individuals who have an inflammation or a scar on a measuring area
[12]Individuals whose BMI is over 25
[13]Individuals whose systolic blood pressure is over 160mmHg or diastolic pressure is over 100mmHg
[14]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day)
[15]Individuals who are a smoker
[16]Individuals who participated in other clinical studies in the past 3 months
[17]Individuals whose SMI score is over 66
[18]Individuals who have a history of ovarian resection or hysterectomy
[19]Individuals who are or are posslibly, or are lactating
[20]Individuals judged inappropriate for the study by the principal
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Shuji Nakata
Organization Medical Corporation Bokushinkai CLINTEXE Clinic
Division name Director
Zip code
Address 4F Atago Green Hills Mori Tower 2-5-1 Atago Minato-ku Tokyo 105-6204, JAPAN
TEL 03-5405-1059
Email info@tes-h.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Toshiyasu Tamura
Organization TES Holdings Co., Ltd.
Division name Division of Clinical Trial, Department of Development for Clinical Trials
Zip code
Address 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, Japan
TEL 03-6801-8480
Homepage URL
Email info@tes-h.co.jp

Sponsor
Institute TES Holdings Co., Ltd.
Institute
Department

Funding Source
Organization SEEMS Bionics Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 09 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 08 Month 23 Day
Date of IRB
Anticipated trial start date
2016 Year 09 Month 21 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 09 Month 07 Day
Last modified on
2017 Year 02 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027257

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.